Technology Bundle ID

Controlled Expression and Assembly of Human Group-C Rotavirus-like Particles for Creation of Rotavirus Diagnostic Assays and Improved Vaccine Formulations

Linked ID
Lead Inventors
Baoming Jiang (CDC)
Development Stages
Pre-Clinical (in vitro)
Development Status
In vitro data available
CDC researchers have developed methods of producing unlimited quantities of Group-C (GpC) rotavirus antigens. GpC rotaviruses are a major, worldwide cause of acute gastroenteritis in children and adults that is distinct from Group-A rotavirus. However, GpC rotaviruses cannot be grown in culture, resulting in a lack of tools for detection and treatment of GpC rotavirus disease. Consequently, the true clinical burden of GpC rotavirus disease has not been clearly established.

This technology allows for the expression of the three major capsid proteins (VP2, VP6 and VP7) of GpC rotavirus by recombinant baculovirus and assembly of virus-like particles (2-6-7 and/or 6-7) within insect cells. Further, this CDC generated technology allows for the large-scale access to GpC rotavirus antigens, previously infeasible, and will permit use of these novel virus-like particles for the development of rotavirus diagnostic assays and improved vaccine formulations.

Commercial Applications
  • Development or improvement of rotavirus vaccines
  • Rotavirus vaccine composition research
  • Childhood illness vaccination programs and rotavirus monitoring endeavors
  • Development of novel rotavirus diagnostic tools
Competitive Advantages
  • Permits large-scale production of Group-C rotavirus antigens, previously impractical
  • Produced virus-like particles/antigens can be used for rotavirus vaccines, other immunogenic uses and/or sero-diagnostic assay development
  • Diagnostic tools for Group-C rotavirus are currently unavailable; this technology fulfills an unmet need for accurate assessment of the Group-C rotaviral global health burden

Request More Info

Licensing Contact: